Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.

Results of the landmark MIROCALS clinical trial, published in The Lancet, show a low-dose interleukin-2 (IL2LD) is safe, compared to placebo.Although ...

While IL2 LD is not currently licensed for MND/ALS treatment ... and logistical support from WGK Ltd and ICON plc. The clinical trial involved seven MND/ALS Centres in the UK (six in England, one in ...

Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is ...

DUBLIN 18, Ireland (AP) — Icon PLC (ICLR) on Wednesday reported first-quarter earnings of $154.2 million. The Dublin 18, Ireland-based company said it had profit of $1.90 per share. Earnings ...

Share Repurchases: $250 million at an average price of $184 per share. Icon PLC (NASDAQ:ICLR) reported better-than-expected adjusted EBITDA margin performance of 19.5% for Q1 2025, demonstrating ...